20.500.12556/DiRROS-24623 Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism Aims To compare the effects of semaglutide and testosterone replacement therapy (TRT) on semen quality and parameters of functional hypogonadism (FH) in men with type 2 diabetes mellitus and obesity. Materials and Methods We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46–60] years, BMI 35.9 [32.8–38.7] kg/m2) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10–12 weeks for 24 weeks. Semen analysis and parameters of FH were measured at baseline and after 24 weeks of treatment. Participants completed questionnaires of the International Index of Erectile Function-15 (IIEF-15) and the Aging Symptoms in Men (AMS). Results The quality of baseline sperm parameters of our study cohort was poor, below the 5th percentile of reference values. In the SEMA group, there was a significant increase in morphologically normal sperm from baseline to the end of the study (2% [2; 3.5] vs. 4% [2; 5.5]; p = 0.012), whereas sperm concentration and total number decreased significantly in the TRT group. Compared to TRT, the SEMA group had a significantly higher number of morphologically normal sperm, sperm concentration and total number. Both groups experienced an increase in total testosterone and improvement in the AMS score, whereas the IIEF-15 score significantly improved only in the TRT group. Conclusion Semaglutide markedly improved sperm morphology, total testosterone levels and symptoms of hypogonadism. These findings highlight semaglutide's potential as a therapeutic approach for men with obesity-related FH who desire fertility. functional hypogonadism obesity semaglutide funkcionalni hipogonadizem debelost semaglutid true false true Angleški jezik Slovenski jezik Neznano 2025-12-09 12:16:21 2025-12-09 12:16:21 2025-12-10 03:45:45 0000-00-00 00:00:00 2025 0 0 str. 519-528 iss. 2 Vol. 27 Feb. 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616.4 1462-8902 10.1111/dom.16042 214345475 RAZ_Gregoric_Nadan_2025.pdf RAZ_Gregoric_Nadan_2025.pdf 1 C9E22AD31E99CD4AEA3DDF1AAC3B31A8 056559ae23011e50f695e6f4e70c30a61ef7eee87f7b1d8b000586834401b5ab 9bb2b74d-d4f0-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36739 https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16042 1 7f9ebad1-d4f0-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36738 Univerzitetni klinični center Ljubljana 0 0 0